GSK Divesting Horlicks Nutritional Business, Investing In OTC Production
This article was originally published in The Rose Sheet
Executive Summary
Latest consumer health investment was $36m upgrade to a Canadian facility, which by mid-2019 will begin making Voltaren OTC topical gel products. GSK's next move in consumer health divestment is its pending sale of its Horlicks business.
You may also be interested in...
Horlicks Brings Unilever 'Transformative' Nutritional Deal, Market Challenges
Firm's Hindustan Unilever division will merge with s GSK Consumer Healthcare India which has had total sales around €550m so far in 2018, primarily through the Horlicks and Boost brands and with nearly 90% of the revenues in India. Also will acquire 82% stake in GSK Bangladesh and other GSK commercial operations and assets outside India, paying €3.3bn in combination of cash and shares in Hindustan Unilever.
Health Warrior To PepsiCo: Latest Healthy Pivot Among Food And Beverage Giants
PepsiCo purchases Health Warrior, US startup marketing plant-based nutrition products with “superfood” ingredients such as chai seeds and pumpkin seed protein. Beverage giant says it will continue to build healthy snacks and beverage segment, which already is 50% of its portfolio
GSK’s Horlicks Review Plan - Some Early Expectations In India
A potential sale of Horlicks could impact market dynamics significantly in India where the popular malt beverage holds a dominant position but has seen competition build up. GlaxoSmithKline, though, has underscored that the review plan had nothing to do with the product’s "critical mass".